Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
NCT ID: NCT01555710
Last Updated: 2013-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
548 participants
INTERVENTIONAL
2012-05-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.
Secondary efficacy endpoints include ORR, PFS, duration of response and changes in QOL and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.
An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
NCT01154140
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00083161
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
NCT01441128
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
NCT04254471
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
NCT01168791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Palifosfamide-tris plus Carboplatin and Etoposide
Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
Carboplatin
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Palifosfamide-tris
130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
Etoposide
100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
Carboplatin plus Etoposide
Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
Etoposide
100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
Carboplatin
AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Palifosfamide-tris
130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
Etoposide
100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
Carboplatin
AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
* ECOG Performance Status of 0, 1 or 2.
* Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
* Male and female patients must agree to use a highly reliable method of birth control during study participation.
* Able to provide informed consent
Exclusion Criteria
* Known allergy to any of the study drugs or their excipients.
* Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
* Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
* Currently pregnant or nursing.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alaunos Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, United States
University of Southern California
Los Angeles, California, United States
Redwood Regional Oncology Group
Santa Rosa, California, United States
Christiana Care Health Services
Newark, Delaware, United States
Baptist Cancer Institute
Jacksonville, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Sant Lucie, Florida, United States
Peachtree Hematology Oncology Consultants
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Medical and Surgical Specialists, LLC
Galesburg, Illinois, United States
Illinois Cancer Specialists
Niles, Illinois, United States
Central Indiana Cancer Centers
Fishers, Indiana, United States
Goshen Center for Cancer Care
Goshen, Indiana, United States
Indiana University
Indianapolis, Indiana, United States
Horizon Oncology Center
Lafayette, Indiana, United States
Indiana University Health Ball Memorial Hospital
Muncie, Indiana, United States
University of Kansas Hospital
Overland Park, Kansas, United States
Central Baptist Hospital
Lexington, Kentucky, United States
Medical Oncology, LLC
Baton Rouge, Louisiana, United States
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, United States
Metro Health Cancer Center
Wyoming, Michigan, United States
Saint Mary's Medical Center
Duluth, Minnesota, United States
Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
Morristown, New Jersey, United States
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
New York Oncology Hematology, PC
Albany, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
The Christ Hospital
Cincinnati, Ohio, United States
Dayton Cancer Center, Medical Oncology Hematology Associates
Dayton, Ohio, United States
Medical Oncology Associates Of Wyoming Valley, PC
Kingston, Pennsylvania, United States
Charleston Hematology Oncology Associates, PA
Charleston, South Carolina, United States
Texas Oncology-Medical City Dallas
Dallas, Texas, United States
Texas Oncology- Baylor, Charles A. Sammons Cancer Center
Dallas, Texas, United States
University of Texas Medical Branch at Galveston
Galveston, Texas, United States
Oncology Consultants, PA
Houston, Texas, United States
Texas Oncology, PA
Wichita Falls, Texas, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
Fairfax Northern Virginia Hematology-Oncology, PC
Fairfax, Virginia, United States
Swedish Medical Center
Seattle, Washington, United States
Wisconsin Institutes for Medical Research
Madison, Wisconsin, United States
Southern Medical Day Oncology Care Centre
Wollongong, New South Wales, Australia
CancerCare Manitoba
Winnipeg, Manitoba, Canada
R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
Oshawa, Ontario, Canada
Hôpital Laval
Sainte-Foy, Quebec, Canada
Centre Hospitalier Lyon Sud
Pierre Bénité, Auvergne-Rhône-Alpes, France
Centre François Baclesse
Caen, Basse-normandie, France
Centre Hospitalier Universitaire -Hôpital Morvan
Brest, Brittany Region, France
Centre Hospitalier Universitaire, Hopital Bretonneau
Tours, Centre-Val de Loire, France
Hôpital du Cluzeau
Limoges, Limousin, Lorraine, France
Institut de Cancérologie de l'Ouest - René Gauducheau
Saint-Herblain, Pays de la Loire Region, France
Hôpital Saint Joseph
Marseille, Provence-Alpes-Côte d'Azur Region, France
Centre Paul Strauss
Strasbourg, , France
Debreceni Egyetem Orvos és Egészségtudományi Centrum
Debrecen, Hajdú-Bihar, Hungary
Mátrai Gyógyintézet
Mátraháza, Heves County, Hungary
Rambam Medical Center
Haifa, , Israel
Hadassah Medical Organization, Ein Kerem
Jerusalem, , Israel
Meir Hospital Sapir Medical Center
Kfar Saba, , Israel
Western Gallilee Medical Center
Nahariya, , Israel
Rabin Medical Center Beilinson Campus
Petah Tikva, , Israel
Istituto Nazionale per la Ricerca sul Cancro
Genova, Genova, Italy
Presidio Ospedaliero S. Chiara
Trento, Trento, Italy
Azienda Ospedaliera Ospedale Niguarda Ca' Granda
Milan, , Italy
Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, Poland
Wojewódzkie Centrum Onkologii
Gdansk, Pomeranian Voivodeship, Poland
Specjalistyczny Szpital im. Alfreda Sokolowskiego
Szczecin, West Pomeranian Voivodeship, Poland
Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
Ufa, Bashkortostan Republic, Russia
Ivanovo Regional Oncology Centre
Ivanovo, Ivanovo Oblast, Russia
City Oncology Hospital # 62
Moscow Region, Moscow, Russia
State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
Arkhangelsk, Primorskiy (Maritime) Kray, Russia
Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
Kazan', Tatarstan Republic, Russia
State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
Chelaybinsk, , Russia
Cancer Research Center n.a. N.N. Blokhin
Moscow, , Russia
GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
Nizhny Novgorod, , Russia
State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
Saint Petersburg, , Russia
Saint-Petersburg State Medical University n. a. I. P. Pavlov
Saint Petersburg, , Russia
State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
Yaroslavl, , Russia
China Medical University Hospital
Taichung, , Taiwan
Wythenshawe Hospital
Manchester, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPM3002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.